The FDA urged clinical trial sponsors and investigators to report results for registered studies after an internal review found that outcomes were missing for roughly 30% of registered clinical studies. In response, the agency sent reminders to about 2,200 entities, including drug and device companies and researchers. The move targets gaps in transparency tied to the reporting of study results, which can affect clinicians’ ability to interpret evidence and regulators’ confidence in the totality of data. By escalating outreach, the FDA is emphasizing compliance expectations for trial reporting. For the industry, the action signals continuing pressure on operational processes around result submission timelines and public availability. Companies with multiple registered studies may need to audit reporting status to reduce regulatory risk. The reminders also reinforce that registries are becoming a stronger enforcement surface, even where formal penalties are not immediately described.